Innovation has helped drug firms take on Big PharmaByRadhieka Pandeya
Let’s break it down further: First up, we start by looking at the capital market. Over the past decade, China's innovative drug sector has attracted more than 1 trillion RMB in funding. For a strategic emerging industry like this, that kind of cash is like rocket fuel for innovation. ...
reach $57.34 billion by 2032, more pharmaceutical companies are outsourcing manufacturing to optimize operations, minimize capital expenditure, and gain access to specialized expertise. This approach allows them to focus on innovation and drug development while ensuring high standards of manufacturing ...
7-ADCA, D-7ACA) and penicillin intermediates (6-APA, penicillin G potassium salt) ranking at the forefront among those of its Chinese peers. Chuanning Biotech was the first to apply biological fermentation and extraction technologies
When it comes to the development of new drugs as of January 2024, Swiss-based company Roche was the leader among the global top pharmaceutical companies. With 218 products in the R&D pipeline, Roche leads the ranking, closely followed by U.S. company Pfizer. Among the global top 15 companie...
When utilising the wide range of practical applications available, pharma companies using AI have the potential to transform key aspects of the industry while simultaneously driving innovation. Among these uses are data management, drug discovery, and clinical trial design. ...
companies, accompanied by Swiss pharma giants Roche and Novartis. Prescription and over-the-counter drugsThe total global prescription drug market –including generic and orphan drugs – was estimated at 1.12 trillion U.S. dollars for 2022. Especially the orphan drug market is a major driver and ...
As post-pandemic recovery begins, big pharma remains in the spotlight. Jesse Mendelsohn explores pharma's priorities on pricing, profits and progress post-Covid. It goes without saying that if pharmaceutical companies are not profitable, they will not su
As of now, the company has been listed in the Fortune Global 500 list for five consecutive years, and this year it has risen to 411th place, ranking at the forefront of pharmaceutical companies in China. With the mission of "perseverance and dedication to improving the quality of people's...
Three prominent Chinese executives discuss the progress of local companies in drug innovation and the evolving regulatory environment.